Core Viewpoint - Warner Pharmaceuticals (688799) announced participation in the 11th batch of national centralized drug procurement organized by the National Organization for Drug Procurement Office, with its product, Benidipine Hydrochloride Tablets, expected to win the bid for this centralized procurement [1] Group 1 - Warner Pharmaceuticals is involved in the national centralized drug procurement process [1] - The company is targeting its Benidipine Hydrochloride Tablets for potential procurement [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has participated in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office, with its product, Benidipine Hydrochloride Tablets, expected to win the bid for this procurement [1] Group 1 - The company announced its participation in a significant national drug procurement event [1] - The product involved in the bidding is Benidipine Hydrochloride Tablets [1] - The procurement event is organized by the National Organization for Drug Procurement Office [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) announced participation in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with the intention to bid for the hydrochloride benidipine tablets [1] Group 1 - The company is set to participate in a significant national drug procurement process [1] - The hydrochloride benidipine tablets are the specific product the company aims to bid for in this procurement [1]

二、本次拟中标对公司的影响 证券代码：688799 证券简称：华纳药厂 公告编号：2025-082 湖南华纳大药厂股份有限公司自愿披露 关于公司参与全国药品集中采购拟中标的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 10 月 27 日，湖南华纳大药厂股份有限公司（以下简称"公司"） 参加了国家组织药品联合采购办公室（以下简称"联合采购办公室"）组织的第 十一批全国药品集中采购的投标工作，公司盐酸贝尼地平片拟中标本次集中采购。 现将有关情况公告如下： 注：上述拟中标信息均以联合采购办公室发布的最终数据为准。 公司拟中标产品的采购合同签订等后续事项尚具有不确定性。公司将密切关 注该事项的进展情况并及时履行信息披露义务，敬请广大投资者谨慎决策，注意 投资风险。 特此公告。 湖南华纳大药厂股份有限公司董事会 2025 年 10 月 29 日 公司拟中标产品盐酸贝尼地平片于 2024 年 11 月通过受让取得，具体情况详 见公司于 2024 年 11 月 20 日在上海证券交易所网站披露的《湖南华纳大药厂股 份 ...

Core Viewpoint - The company has participated in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement, with the intention to win the bid for Benidipine Hydrochloride Tablets, which are used for treating primary hypertension and angina pectoris [1] Group 1: Product and Pricing - The product in question is Benidipine Hydrochloride Tablets, with a specification of 8mg and packaging of 28 tablets per box [1] - The proposed winning bid price is 7.19 yuan per box [1] Group 2: Sales Projections - The company anticipates sales revenue of 166,300 yuan in 2024 and 5,097,600 yuan in the first half of 2025 [1] - If the procurement contract is signed and executed, it will help further expand sales scale, enhance market share, and improve brand influence [1] Group 3: Impact on Future Performance - The successful bid and subsequent contract execution are expected to have a positive impact on the company's future operating performance [1]

Core Points - The company has received approval from the National Medical Products Administration for the production of two chemical raw materials: Isoproterenol Hydrochloride and Dexamethasone Tartrate [1][2][3] - The approval indicates that these raw materials meet the national drug review technical standards and will enhance the company's product line and core competitiveness [5] Raw Material Registration Information - **Isoproterenol Hydrochloride**: - Registration Number: Y20240000173 - Application: Domestic production of chemical raw materials - Packaging Specifications: 0.1kg, 0.2kg, 0.5kg, 1kg, 2kg, 3kg, 5kg [1] - Production Company: Hunan Warner Pharmaceutical Chiral Drugs Co., Ltd. - Production Address: Changsha City, Hunan Province [1] - Approval Conclusion: Complies with drug registration requirements [1][4] - **Dexamethasone Tartrate**: - Registration Number: Y20240000250 - Application: Domestic production of chemical raw materials - Packaging Specifications: 100g, 200g, 500g, 1kg, 2kg, 3kg [2] - Production Company: Hunan Warner Pharmaceutical Chiral Drugs Co., Ltd. - Production Address: Changsha City, Hunan Province [2] - Approval Conclusion: Complies with drug registration requirements [2][4] Drug Information - **Isoproterenol Hydrochloride**: Used for treating cardiogenic or infectious shock and complete atrioventricular block, cardiac arrest [4] - **Dexamethasone Tartrate**: Used for blood pressure control in acute hypotensive states and as an adjunct in cardiac arrest and severe hypotension [5]

Core Insights - Warner Pharmaceutical's subsidiary has received approval for two chemical raw materials, indicating compliance with national drug review standards and enhancing the company's product line and core competitiveness [1][2] Group 1: Regulatory Approvals - Warner Pharmaceutical's subsidiary, Hunan Warner Pharmaceutical, received approval for isoproterenol hydrochloride and racemic norepinephrine raw materials, marking the 7th and 8th raw material approvals in 2023 [1] - The company now has a total of 72 raw material varieties, with 55 approved for use in formulations [1] Group 2: Product Applications - Isoproterenol hydrochloride is used in injection form for treating cardiogenic or infectious shock and complete atrioventricular block [1] - Racemic norepinephrine is utilized for blood pressure control in acute hypotensive states and as an adjunct treatment for cardiac arrest and severe hypotension [1] Group 3: Market Relevance - Both isoproterenol hydrochloride and racemic norepinephrine injections are common emergency medications and are included in the "clinically essential and easily short-supplied drugs" list [1] - Racemic norepinephrine injection has been included in the 10th batch of national centralized procurement [1]

Group 1 - Warner Pharmaceuticals announced that its wholly-owned subsidiary, Hunan Warner Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of Isoproterenol Hydrochloride and Dextroamphetamine Tartrate [2] - The approval notification has been published on the Drug Evaluation Center (CDE) platform of the National Medical Products Administration [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）全资子公司湖南 华纳大药厂手性药物有限公司（以下简称"手性药物"）收到国家药品监督管理 局签发的盐酸异丙肾上腺素、重酒石酸去甲肾上腺素《化学原料药上市申请批准 通知书》（通知书编号：2025YS00924、2025YS00925），并在国家药品监督管理 局药品审评中心（CDE）"原辅包登记信息"平台公示。具体情况如下： 证券代码：688799 证券简称：华纳药厂 公告编号：2025-081 湖南华纳大药厂股份有限公司 自愿披露关于子公司原料药获得上市申请批准通知 书的公告 一、原料药登记信息 （一）盐酸异丙肾上腺素 1、化学原料药名称：盐酸异丙肾上腺素 2、登记号：Y20240000173 3、申请事项：境内生产化学原料药上市申请 4、包装规格：0.1kg/桶、0.2kg/桶、0.5kg/桶、1kg/桶、2kg/桶、3kg/桶、5kg/ 桶 5、生产企业：湖南华纳大药厂手性药物有限公司 6、生产地址：湖南省长沙市望城区铜官循 ...

Core Insights - Warner Pharmaceuticals announced that its wholly-owned subsidiary, Hunan Warner Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing application of Isoproterenol Hydrochloride and Levonordefrin Tartrate [1] Product Development - Isoproterenol Hydrochloride is indicated for the treatment of cardiogenic or infectious shock, while Levonordefrin Tartrate is used to manage blood pressure in acute hypotensive states [1] Competitive Advantage - The approval will enrich the company's product line and enhance its core competitiveness in the pharmaceutical market [1]